

May 18, 2023

## Q4FY23 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

### **Change in Estimates**

	Cu	rrent	Pre	vious
	FY24E	FY25E	FY24E	FY25E
Rating	ACCU	MULATE	ACCU	MULATE
Target Price	1	520		480
Sales (Rs. m)	1,83,773	1,97,657	1,81,140	1,95,302
% Chng.	1.5	1.2		
EBITDA (Rs. m	n) 39,496	43,381	39,559	43,422
% Chng.	(0.2)	(0.1)		
EPS (Rs.)	25.4	28.0	24.9	26.9
% Chng.	2.0	4.4		

### **Key Financials - Consolidated**

Y/e Mar	FY22	FY23	FY24E	FY25E
Sales (Rs. m)	1,51,102	1,72,374	1,83,773	1,97,657
EBITDA (Rs. m)	31,857	35,755	39,496	43,381
Margin (%)	21.1	20.7	21.5	21.9
PAT (Rs. m)	22,419	19,649	25,689	28,383
EPS (Rs.)	21.9	19.4	25.4	28.0
Gr. (%)	1.8	(11.3)	30.7	10.5
DPS (Rs.)	4.0	4.0	4.5	5.0
Yield (%)	0.8	0.8	0.9	1.0
RoE (%)	15.0	11.4	13.8	13.7
RoCE (%)	12.8	14.3	16.3	16.5
EV/Sales (x)	3.6	3.0	2.8	2.5
EV/EBITDA (x)	17.3	14.5	12.9	11.5
PE (x)	23.2	26.2	20.0	18.1
P/BV (x)	3.1	2.9	2.6	2.4

Key Data	ZYDU.BO   ZYDUSLIF IN
52-W High / Low	Rs.531 / Rs.330
Sensex / Nifty	61,432 / 18,130
Market Cap	Rs.514bn/ \$ 6,226m
Shares Outstanding	1,012m
3M Avg. Daily Value	Rs.453.04m

### **Shareholding Pattern (%)**

Promoter's	74.98
Foreign	3.42
Domestic Institution	13.26
Public & Others	8.34
Promoter Pledge (Rs bn)	-

### Stock Performance (%)

	1M	6M	12M
Absolute	(1.5)	26.5	46.2
Relative	(4.3)	27.0	29.0

### Param Desai

paramdesai@plindia.com | 91-22-66322259

Akshaya Shinde

akshayashinde@plndia.com | 91-22-66322490

## Zydus Lifesciences (ZYDUSLIF IN)

### Rating: ACCUMULATE | CMP: Rs508 | TP: Rs520

## Sustainability of US sales is key

### **Quick Pointers:**

- Guided for high single digit growth in US sales in FY24E; Q1FY24 will also continue to see higher US sales
- Expect 100-150 bps margin improvement in FY24.

Zydus Lifesciences (ZYDUSLIF) Q4 EBITDA of Rs13bn (up 55% QoQ) was sharply ahead of our estimate aided by higher US sales led by gRevlimid and gTrokendi. We believe that company's steady domestic franchise, strong balance sheet and potential new launches in US will help negate pricing pressure and likely competition in some key products like gAsacol. Moreover, ZYDUSLIF is also working on robust pipeline of complex products including injectables, transdermals, NCE, biosimilars and vaccines which are expected to materialize over next 2–3 years. Our FY24/25E EPS stands marginally stands increased by 1%/3%. We maintain our 'Accumulate' rating with revised TP of Rs520 (Rs480 earlier), based on FY25E earnings.

- Strong revenue growth of 32% YoY: ZYDUSLIF's Q4FY23 sales increased by 32% YoY (up 18% QoQ) to Rs50bn vs our estimate of Rs45bn aided by higher US sales and other operating income. Domestic formulation sales increased by 11% YoY; above our estimate. Ex-COVID and divestment of portfolio growth came at 12% YoY. Consumer business grew healthy by 12% YoY. US sales came in at USD 275mn (our est. of USD 235mn) vs USD 234mn in Q3FY23. The QoQ improvement aided by higher gRevlimid sales and new launches like gTrokendi. Emerging markets growth was up 30% YoY while API saw decline of 8% YoY.
- EBITDA beat aided by higher US sales and other operating income: GM increased by 500bp YoY and 130 bps QoQ to 65% aided by better product mix in US. Other expenses were up by 22% YoY. R&D cost came at Rs3.54bn; up 32% YoY. Staff cost increased by 21% YoY. EBITDA including other operating income came in at Rs 13.1bn vs our estimate of Rs10.6bn. There was forex loss to tune of Rs585mn. Adjusted for exceptional loss and forex loss, PAT came in at Rs9.5bn vs our est of Rs6.6bn.
- Key concall takeaways: (1) In the US, company launched 8 new products in Q4FY23. Successfully launched Topiramate ER capsule in Q4 as first generic player. Product likely to face competition in coming quarters (2) Company received 28 new product approvals during Q4. Moraiya facility completed its pre-approval inspection for the transdermal product by USFDA with EIR report.
  (3) In the US mgt. expects few critical launches in next 3 months and five high value program for FY24 and guided high single digit growth in FY24E. (4) gRevlimid continued to remain important contributor with higher sales expected in FY24 and FY25 (5) Company will continue to beat the market growth in India. (6) Company guided for 8% R&D spend in FY24 and its major spend will be towards innovative portfolio. (7) Saroglitazar Magnesium is undergoing Phase II(b) clinical trials for NASH indication for the US market and received approval from the regulatory authority of Turkey to conduct clinical trials (8) Organic capex for FY23 was to tune of Rs9.6bn. Company remain net cash positive to tune of Rs5.5bn

Y/e March	Q4FY23	Q4FY22	YoY gr. (%)	Q3FY23	QoQ gr. (%)	FY23	FY22	YoY gr. (%)
Net Sales	50,106	38,056	31.7	42,571	17.7	175,803	152,320	15.4
Raw Material	16,960	14,958	13.4	15,104	12.3	63,101	55,665	13.4
% of Net Sales	33.8	39.3		35.5		35.9	36.5	
Personnel Cost	7,239	5,998	20.7	6,890	5.1	27,656	24,341	13.6
% of Net Sales	14.4	15.8		16.2	(10.7)	15.7	16.0	
Others	12,766	10,505	21.5	12,069	5.8	45,862	39,452	16.2
% of Net Sales	25.5	27.6		28.4		26.1	25.9	
Total Expenditure	36,965	31,461	17.5	34,063	8.5	136,619	119,458	14.4
EBITDA	13,141	6,595	99.3	8,508	54.5	39,184	32,862	19.2
Margin (%)	26.2	17.3		20.0		22.3	21.6	
Depreciation	1,786	1,854	(3.7)	1,816	(1.7)	7,227	7,130	1.4
EBIT	11,355	4,741	139.5	6,692	69.7	31,957	25,732	24.2
Other Income	(207)	1,373	(115.1)	1,437	(114.4)	1,281	2,792	(54.1)
Interest	277	385	(28.1)	328	(15.5)	1,299	1,270	2.3
PBT	10,871	5,729	89.8	7,801	39.4	31,939	27,254	17.2
Extra-Ord. Inc./Exps.	6,013	-		-		6,042	(1,127)	
Total Taxes	1,372	1,092	25.6	1,952	(29.7)	5,878	5,117	14.9
ETR (%)	12.6	19.1		25.0		18.4	18.8	
Minority interest	(498)	(513)		376		(370)	(848)	
Reported PAT	2,988	4,124	(27.5)	6,225	(52.0)	19,649	22,416	(12.3)


Exhibit 1: 4QFY22 Result Overview (Rs mn): Strong performance led by US formulations business

Source: Company, PL

### Exhibit 2: Higher US sales aided by gRevlimid and gTrokendi

Major Sources of Revenues	Q4FY23	Q4FY22	YoY gr. (%)	Q3FY23	QoQ gr. (%)	FY23	FY22	YoY gr. (%)
Domestic	19,971	17,970	11.1	16,436	21.5	71,449	67,905	5.2
% of Net Sales	41.2%	48.0%		39.5%		42.3%	45.7%	
Formulation	12,896	11,640	10.8	12,316	4.7	49,111	48,121	2.1
% of Net Sales	26.6%	31.1%		29.6%		29.1%	32.4%	
Consumer HC & Others	7,075	6,330	11.8	4,120	71.7	22,338	19,784	12.9
% of Net Sales	14.6%	16.9%		9.9%		13.2%	13.3%	
Exports	28,554	19,448	46.8	25,162	13.5	97,330	80,615	20.7
% of Net Sales	58.8%	52.0%		60.5%		57.7%	54.3%	
Formulation	26,918	17,616	52.8	23,033	16.9	90,245	72,830	23.9
% of Net Sales	55.5%	47.1%		55.4%		53.5%	49.0%	
North America	22,525	14,233	58.3	19,250	17.0	74,451	58,384	27.5
EU	700	633	10.6	705	(0.7)	2,560	2,522	1.5
EM	3,693	2,750	34.3	3,078	20.0	13,234	11,924	11.0
	1,251	1,363	(8.2)	1,881	(33.5)	5,473	5,703	(4.0)
API	19,971	17,970	11.1	16,436	21.5	71,449	67,905	5.2
% of Net Sales	41.2%	48.0%		39.5%		42.3%	45.7%	


Source: Company, P



### Exhibit 3: Robust performance across key therapies


Source: Company, PL

### Exhibit 4: Robust growth driven by new launches and volume expansion




Source: Company, PL

### Exhibit 5: EU sales (Rs m) & QoQ Gr(%): Growth remained healthy




Source: Company, PL



### Exhibit 6: Base business continued to show healthy performance

Source: Company, PL





Source: Company, PL

## Zydus Lifesciences

## **Financials**

### Income Statement (Rs m)

Y/e Mar	FY22	FY23	FY24E	FY25E
Net Revenues	1,51,102	1,72,374	1,83,773	1,97,657
YoY gr. (%)	4.9	14.1	6.6	7.6
Cost of Goods Sold	55,452	63,101	65,589	70,005
Gross Profit	95,650	1,09,273	1,18,184	1,27,652
Margin (%)	63.3	63.4	64.3	64.6
Employee Cost	24,341	27,656	29,868	32,258
Other Expenses	7,427	8,937	9,659	10,428
EBITDA	31,857	35,755	39,496	43,381
YoY gr. (%)	(5.9)	12.2	10.5	9.8
Margin (%)	21.1	20.7	21.5	21.9
Depreciation and Amortization	7,130	7,227	7,661	8,120
EBIT	24,727	28,528	31,836	35,261
Margin (%)	16.4	16.6	17.3	17.8
Net Interest	1,270	1,299	1,100	900
Other Income	3,800	4,710	2,000	2,200
Profit Before Tax	28,384	25,897	32,736	36,561
Margin (%)	18.8	15.0	17.8	18.5
Total Tax	5,117	5,878	6,547	7,678
Effective tax rate (%)	18.0	22.7	20.0	21.0
Profit after tax	23,267	20,019	26,189	28,883
Minority interest	1,310	1,316	1,200	1,200
Share Profit from Associate	462	946	700	700
Adjusted PAT	22,419	19,649	25,689	28,383
YoY gr. (%)	1.8	(12.4)	30.7	10.5
Margin (%)	14.8	11.4	14.0	14.4
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	22,419	19,649	25,689	28,383
YoY gr. (%)	1.8	(12.4)	30.7	10.5
Margin (%)	14.8	11.4	14.0	14.4
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	22,419	19,649	25,689	28,383
Equity Shares O/s (m)	1,024	1,012	1,012	1,012
EPS (Rs)	21.9	19.4	25.4	28.0

Source: Company Data, PL Research

### Balance Sheet Abstract (Rs m)

Balance Sheet Abstract (NS	<u> </u>			
Y/e Mar	FY22	FY23	FY24E	FY25E
Non-Current Assets				
Gross Block	1,81,315	1,81,922	1,93,922	2,05,922
Tangibles	92,988	93,299	99,454	1,05,608
Intangibles	88,327	88,623	94,468	1,00,314
Acc: Dep / Amortization	58,781	66,008	73,669	81,789
Tangibles	40,871	45,897	51,223	56,869
Intangibles	17,910	20,111	22,446	24,920
Net fixed assets	1,22,534	1,15,914	1,20,253	1,24,133
Tangibles	52,117	47,403	48,231	48,739
Intangibles	70,417	68,511	72,023	75,394
Capital Work In Progress	6,610	11,302	11,302	11,302
Goodwill	-	-	-	-
Non-Current Investments	32,880	15,466	15,466	15,466
Net Deferred tax assets	9,420	10,680	10,680	10,680
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	37,194	34,133	41,448	46,215
Trade receivables	33,403	44,168	42,446	45,677
Cash & Bank Balance	11,069	5,731	15,031	22,784
Other Current Assets	-	-	-	-
Total Assets	2,66,996	2,44,940	2,65,995	2,87,630
Equity				
Equity Share Capital	1,024	1,012	1,012	1,012
Other Equity	1,68,972	1,74,146	1,94,825	2,17,585
Total Networth	1,69,996	1,75,158	1,95,837	2,18,597
Non-Current Liabilities				
Long Term borrowings	3,621	-	-	-
Provisions	6,906	6,372	6,372	6,372
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	38,339	11,632	8,632	5,632
Trade payables	21,378	21,250	24,626	26,501
Other current liabilities	15,634	19,483	19,483	19,483
Total Equity & Liabilities	2,66,996	2,44,940	2,65,995	2,87,630

Source: Company Data, PL Research

# P

### Cash Flow (Rs m)

Y/e Mar	FY22	FY23	FY24E	FY25E
PBT	34,104	37,621	41,496	45,581
Add. Depreciation	7,130	7,227	7,661	8,120
Add. Interest	1,270	1,299	1,100	900
Less Financial Other Income	3,800	4,710	2,000	2,200
Add. Other	(11,198)	(10,981)	(8,761)	(9,020)
Op. profit before WC changes	31,306	35,166	41,496	45,581
Net Changes-WC	(3,515)	(2,358)	(2,217)	(6,123)
Direct tax	(6,746)	(5,920)	(6,547)	(7,678)
Net cash from Op. activities	21,045	26,888	32,733	31,780
Capital expenditures	(12,026)	(10,309)	(12,000)	(12,000)
Interest / Dividend Income	-	-	-	-
Others	7,793	11,822	-	-
Net Cash from Invt. activities	(4,233)	1,513	(12,000)	(12,000)
Issue of share cap. / premium	-	-	-	-
Debt changes	(22,297)	(27,944)	(4,823)	(5,005)
Dividend paid	(3,722)	(2,671)	(5,510)	(6,122)
Interest paid	(1,270)	(1,299)	(1,100)	(900)
Others	12,663	(1,825)	-	-
Net cash from Fin. activities	(14,626)	(33,739)	(11,433)	(12,027)
Net change in cash	2,186	(5,338)	9,300	7,753
Free Cash Flow	9,019	16,579	20,733	19,780

Quarterly Financials (Rs m)	
Y/e Mar	Q1FY23

Y/e Mar	Q1FY23	Q2FY23	Q3FY23	Q4FY23
Net Revenue	40,727	41,347	42,571	50,106
YoY gr. (%)	1.8	10.0	17.0	31.7
Raw Material Expenses	15,093	15,944	15,104	16,960
Gross Profit	25,634	25,403	27,467	33,146
Margin (%)	62.9	61.4	64.5	66.2
EBITDA	8,330	8,153	8,508	13,141
YoY gr. (%)	(14.3)	(9.4)	13.2	99.3
Margin (%)	20.5	19.7	20.0	26.2
Depreciation / Depletion	1,807	1,818	1,816	1,786
EBIT	6,523	6,335	6,692	11,355
Margin (%)	16.0	15.3	15.7	22.7
Net Interest	343	351	328	277
Other Income	659	444	385	378
Profit before Tax	6,839	6,428	6,749	11,456
Margin (%)	16.8	15.5	15.9	22.9
Total Tax	1,184	1,370	1,952	1,372
Effective tax rate (%)	17.3	21.3	28.9	12.0
Profit after Tax	5,655	5,058	4,797	10,084
Minority interest	360	(112)	(376)	498
Share Profit from Associates	-	-	-	-
Adjusted PAT	5,266	5,170	5,173	9,586
YoY gr. (%)	(11.8)	(28.7)	2.1	170.6
Margin (%)	12.9	12.5	12.2	19.1
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	5,266	5,170	5,173	9,586
YoY gr. (%)	(11.8)	(28.7)	2.1	170.6
Margin (%)	12.9	12.5	12.2	19.1
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	5,266	5,170	5,173	9,586
Avg. Shares O/s (m)	1,024	1,024	1,024	1,024
EPS (Rs)	5.2	5.0	6.1	2.9

Key Financial Metrics				
Y/e Mar	FY22	FY23	FY24E	FY25E
Per Share(Rs)				
EPS	21.9	19.4	25.4	28.0
CEPS	28.9	26.6	33.0	36.1
BVPS	166.0	173.1	193.5	216.0
FCF	8.8	16.4	20.5	19.5
DPS	4.0	4.0	4.5	5.0
Return Ratio(%)				
RoCE	12.8	14.3	16.3	16.5
ROIC	9.7	11.9	12.7	13.3
RoE	15.0	11.4	13.8	13.7
Balance Sheet				
Net Debt : Equity (x)	0.2	0.0	0.0	(0.1)
Net Working Capital (Days)	119	121	118	121
Valuation(x)				
PER	23.2	26.2	20.0	18.1
P/B	3.1	2.9	2.6	2.4
P/CEPS	17.6	19.1	15.4	14.1
EV/EBITDA	17.3	14.5	12.9	11.5
EV/Sales	3.6	3.0	2.8	2.5
Dividend Yield (%)	0.8	0.8	0.9	1.0

Source: Company Data, PL Research

### **Key Operating Metrics**


Y/e Mar	FY22	FY23	FY24E	FY25E
US Formulations	58,138	74,451	75,741	78,709
Domestic Formulations	49,678	49,110	54,512	60,508
Consumer Healthcare	19,788	22,338	24,572	27,029
Export Formulations (ex-US)	14,447	15,794	17,399	19,167
API	5,702	5,473	5,856	6,266
Income from JVs	2,079	1,612	1,693	1,777

Source: Company Data, PL Research

## Zydus Lifesciences

## Zydus Lifesciences

### **Price Chart**



### **Recommendation History**

No.	Date	Rating	TP (Rs.) Share I	Price (Rs.)
1	06-Apr-23	Accumulate	480	493
2	06-Feb-23	Accumulate	480	435
3	06-Jan-23	Accumulate	465	433
4	14-Nov-22	Accumulate	465	429
5	06-Oct-22	BUY	425	409
6	11-Aug-22	BUY	425	364
7	07-Jul-22	BUY	450	366
8	23-May-22	BUY	450	357

### **Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Apollo Hospitals Enterprise	BUY	5,400	4,201
2	Aster DM Healthcare	BUY	265	240
3	Aurobindo Pharma	BUY	565	522
4	Cipla	BUY	1,070	937
5	Divi's Laboratories	Hold	2,700	2,890
6	Dr. Reddy's Laboratories	Reduce	4,500	4,867
7	Eris Lifesciences	BUY	780	638
8	Fortis Healthcare	BUY	360	256
9	Glenmark Pharmaceuticals	Accumulate	460	480
10	HealthCare Global Enterprises	BUY	375	274
11	Indoco Remedies	BUY	430	328
12	Ipca Laboratories	Hold	750	741
13	J.B. Chemicals & Pharmaceuticals	BUY	2,350	1,975
14	Krishna Institute of Medical Sciences	BUY	1,660	1,415
15	Lupin	Hold	730	750
16	Max Healthcare Institute	BUY	565	523
17	Narayana Hrudayalaya	BUY	965	760
18	Sun Pharmaceutical Industries	BUY	1,175	997
19	Torrent Pharmaceuticals	BUY	1,820	1,578
20	Zydus Lifesciences	Accumulate	480	493

### PL's Recommendation Nomenclature (Absolute Performance)

Buy	:	> 15%
Accumulate	:	5% to 15%
Hold	:	+5% to -5%
Reduce	:	-5% to -15%
Sell	:	< -15%
Not Rated (NR)	:	No specific call on the stock
Under Review (UR)	:	Rating likely to change shortly
		5 · · · · · · · · · · · · · · · · · · ·

### **ANALYST CERTIFICATION**

### (Indian Clients)

We/l, Mr. Param Desai- MBA Finance, Ms. Akshaya Shinde- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### (US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

### **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai- MBA Finance, Ms. Akshaya Shinde- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com